Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2–positive cancer
PM LoRusso, D Weiss, E Guardino, S Girish… - Clinical Cancer …, 2011 - AACR
Abstract Trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor
(HER2)–targeted antibody-drug conjugate, composed of trastuzumab, a stable thioether …
(HER2)–targeted antibody-drug conjugate, composed of trastuzumab, a stable thioether …
[HTML][HTML] Personalized cancer vaccines: clinical landscape, challenges, and opportunities
Tremendous innovation is underway among a rapidly expanding repertoire of promising
personalized immune-based treatments. Therapeutic cancer vaccines (TCVs) are attractive …
personalized immune-based treatments. Therapeutic cancer vaccines (TCVs) are attractive …
[HTML][HTML] Bioactive compounds in oxidative stress-mediated diseases: Targeting the NRF2/ARE signaling pathway and epigenetic regulation
Oxidative stress is a pathological condition occurring due to an imbalance between the
oxidants and antioxidant defense systems in the body. Nuclear factor E2-related factor 2 …
oxidants and antioxidant defense systems in the body. Nuclear factor E2-related factor 2 …
[HTML][HTML] Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast cancer …
…, IE Krop, RA Michaelson, S Girish… - Journal of Clinical …, 2011 - scholarship.miami.edu
Purpose The antibody-drug conjugate trastuzumab-DM1 (T-DM1) combines the biologic
activity of trastuzumab with targeted delivery of a potent antimicrotubule agent, DM1, to …
activity of trastuzumab with targeted delivery of a potent antimicrotubule agent, DM1, to …
[PDF][PDF] Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
Purpose Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to
specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-positive cells. This …
specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-positive cells. This …
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer who were previously treated …
…, E Guardino, M Lu, M Zheng, S Girish… - Journal of clinical …, 2012 - ascopubs.org
Purpose To determine whether the antibody-drug conjugate trastuzumab emtansine (T-
DM1), which combines human epidermal growth factor receptor 2 (HER2)–targeted delivery …
DM1), which combines human epidermal growth factor receptor 2 (HER2)–targeted delivery …
[HTML][HTML] Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
S Girish, M Gupta, B Wang, D Lu, IE Krop… - Cancer chemotherapy …, 2012 - Springer
Abstract Purpose Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate
comprising trastuzumab and DM1, a microtubule polymerization inhibitor, covalently bound …
comprising trastuzumab and DM1, a microtubule polymerization inhibitor, covalently bound …
[PDF][PDF] Clock regulation of metabolites reveals coupling between transcription and metabolism
…, LJ Francey, S Mukherjee, S Girish… - Cell metabolism, 2017 - cell.com
The intricate connection between the circadian clock and metabolism remains poorly
understood. We used high temporal resolution metabolite profiling to explore clock …
understood. We used high temporal resolution metabolite profiling to explore clock …
[HTML][HTML] Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability
…, J Tibbitts, S Kaur, O Saad, JH Yi, S Girish… - Toxicology and applied …, 2013 - Elsevier
Abstract Trastuzumab emtansine (T-DM1) is the first antibody-drug conjugate (ADC)
approved for patients with human epidermal growth factor receptor 2 (HER2)-positive …
approved for patients with human epidermal growth factor receptor 2 (HER2)-positive …
Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)
…, D Hartley, MX Sliwkowski, S Girish… - Clinical Cancer …, 2015 - AACR
Abstract Purpose: Trastuzumab-emtansine (T-DM1) is an antibody–drug conjugate (ADC)
comprising the cytotoxic agent DM1 conjugated to trastuzumab with a stable linker …
comprising the cytotoxic agent DM1 conjugated to trastuzumab with a stable linker …